Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma

NCT00725582

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy men and women 18 to 60 yrs with mild allergic asthma

2. only asthma med is short-acting bronchodilator used not more than twice weekly

3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Upper respiratory infection or asthma exacerbation with 4 weeks of screening


2. Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of
test article administration


3. Positive radiographic findings indicative of respiratory disease other than asthma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaEvaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
NCT01172808
  1. Huntington Beach, California
  2. Mission Viejo, California
  3. San Diego, California
  4. Wheat Ridge, Colorado
  5. Coeur d'Alene, Idaho
  6. Normal, Illinois
  7. South Bend, Indiana
  8. Baltimore, Maryland
  9. North Dartmouth, Massachusetts
  10. North Dartmouth, Massachusetts
  11. Minneapolis, Minnesota
  12. Bellevue, Nebraska
  13. Boys Town, Nebraska
  14. Omaha, Nebraska
  15. Winston-Salem, North Carolina
  16. Oklahoma City, Oklahoma
  17. Charleston, South Carolina
  18. Easely, South Carolina
  19. Dallas, Texas
  20. Seattle, Washington
  21. Tacoma, Washington
  22. Juiz de Fora,
  23. Porto Alegre,
  24. Porto Alegre,
  25. Porto Alegre,
  26. Rio de Janeiro - RJ,
  27. Beijing,
  28. Beijing,
  29. Beijing,
  30. Beijing,
  31. Changsha,
  32. Chengdu,
  33. Chengdu,
  34. Chongqing,
  35. Guangzhou,
  36. Kunming,
  37. Qingdao,
  38. Shanghai,
  39. Shenyang,
  40. Shenyang,
  41. Xi'An,
  42. Guatelama City,
  43. Guatelmala city,
  44. Guatelmala City,
  45. Guatemala City,
  46. Guatemala city,
  47. Banglore,
  48. Chennai,
  49. Coimbatore,
  50. Coimbatore,
  51. Hyderabad,
  52. Jaipur,
  53. Nagpur,
  54. Pune,
  55. Pune,
  56. Adachi-ku, Tokyo,
  57. Ako, Hyogo,
  58. Chiyoda-ku, Tokyo,
  59. Chuo-ku, Tokyo,
  60. Chuo-ku, Tokyo,
  61. Fujioka, Gunma,
  62. Himeji, Hyogo,
  63. Hitachi, Ibaraki,
  64. Iwamizawa, Hokkaido,
  65. Kanazawa, Ishikawa,
  66. Kitakami, Iwate,
  67. Kitakami, Iwate,
  68. Koga, Ibaraki,
  69. Koganei, Tokyo,
  70. Komaki, Aichi,
  71. Kunitachi, Tokyo,
  72. Mito, Ibaraki,
  73. Osaka, Osaka,
  74. Ota-ku, Tokyo,
  75. Sapporo, Hokkaido,
  76. Sendai, Miyagi,
  77. Sendai, Miyagi,
  78. Setagaya-ku, Tokyo,
  79. Takasaki, Gunma,
  80. Tomakomai, Hokkaido,
  81. Toshima-ku, Tokyo,
  82. Toshima-ku, Tokyo,
  83. Yao, Osaka,
  84. Yokohama, Kanagawa,
  85. Yokohama, Kanagawa,
  86. Daugavpils,
  87. Preili,
  88. Riga,
  89. Riga,
  90. Riga,
  91. Riga,
  92. Riga,
  93. Riga,
  94. Ventspils,
  95. Monterrey,
  96. Zapopan,
  97. Zona Río,
  98. Callao,
  99. Lima,
  100. Lima,
  101. Krakow,
  102. Lodz,
  103. Lodz,
  104. Ostrow Wielkopolska,
  105. Poznan,
  106. Tczew,
  107. Gatchina (Leningradskaya oblast),
  108. Moscow,
  109. Moscow,
  110. Moscow,
  111. Moscow,
  112. St. Petersburg,
  113. St. Petersburg,
  114. St. Petersburg,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEvaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
NCT01172821
  1. Los Angeles, California
  2. Stockton, California
  3. Centennial, Colorado
  4. Denver, Colorado
  5. Panama City, Florida
  6. Winter Park, Florida
  7. Novi, Michigan
  8. Plymouth, Minnesota
  9. St. Louis, Missouri
  10. Bozeman, Montana
  11. Skillman, New Jersey
  12. Raleigh, North Carolina
  13. Cincinnati, Ohio
  14. Portland, Oregon
  15. Greenville, South Carolina
  16. Union, South Carolina
  17. El Paso, Texas
  18. San Antonio, Texas
  19. Florianopolis,
  20. Porto Alegre,
  21. Sao Paulo,
  22. Sao Paulo,
  23. Chengdu,
  24. Chongqing,
  25. Guangzhou,
  26. Guangzhou,
  27. Haikou,
  28. Kunming,
  29. Nanchang,
  30. Nanjing,
  31. Shanghai,
  32. Shanghai,
  33. Shanghai,
  34. Shanghai,
  35. Xi'An,
  36. Xi'An,
  37. Xuzhou,
  38. Yangzhou,
  39. Yinchuan,
  40. Bogota,
  41. Bogota,
  42. Bogota,
  43. Medelin,
  44. Bamberg,
  45. Berlin,
  46. Berlin,
  47. Berlin,
  48. Berlin,
  49. Berlin,
  50. Frankfurt,
  51. Hamburg,
  52. Koblenz,
  53. Lübeck,
  54. Rüdersdorf,
  55. Wiesbaden,
  56. Witten,
  57. Ahmedabad,
  58. Coimbatore,
  59. Hyderabad,
  60. Jaipur,
  61. Jaipur,
  62. Mumbai,
  63. Mysore,
  64. Nagpur,
  65. Aira, Kagoshima,
  66. Chuo-ku, Tokyo,
  67. Fukuoka, Fukuoka,
  68. Fukuoka, Fukuoka,
  69. Fukuyama, Hiroshima,
  70. Habikino, Osaka,
  71. Hiroshima, Hiroshima,
  72. Itabashi-ku, Tokyo,
  73. Iwata, Shizuoka,
  74. Kanazawa, Ishikawa,
  75. Kishiwada, Osaka,
  76. Kitakyushu, Fukuoka,
  77. Kobe, Hyogo,
  78. Koto-ku, Tokyo,
  79. Kyoto, Kyoto,
  80. Matsusaka, Mie,
  81. Meguro-ku, Tokyo,
  82. Minato-ku, Tokyo,
  83. Minato-ku, Tokyo,
  84. Morioka, Iwate,
  85. Naka-gun, Ibaraki,
  86. Nakano-ku,Tokyo,
  87. Oita,Oita,
  88. Osaka-Sayama, Osaka,
  89. Sapporo, Hokkaido,
  90. Sendai, Miyagi,
  91. Seto, Aichi,
  92. Shinagawa-ku, Tokyo,
  93. Shizuoka, Shizuoka,
  94. Toyota, Aichi,
  95. Urasoe, Okinawa,
  96. Urasoe, Okinawa,
  97. Urasoe, Okinawa,
  98. Yokohama, Kanagawa,
  99. Yotsukaido, Chiba,
  100. Mexico City,
  101. Mexico City,
  102. Monterrey,
  103. Lima,
  104. Lima,
  105. Lima,
  106. Lima,
  107. Lima,
  108. Bialystok,
  109. Bydgoszcz,
  110. Gorzow Wielkopolski,
  111. Krakow,
  112. Poznan,
  113. Sopot,
  114. Wloszczowa,
  115. Wroclaw,
  116. Brasov,
  117. Brasov,
  118. Bucharest,
  119. Bucharest,
  120. Bucharest,
  121. Bucharest,
  122. Bucharest,
  123. Bucuresti,
  124. Constanta,
  125. Iasi,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEfficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680
  1. Denver, Colorado
  2. Columbia, Missouri
  3. Warrensburg, Missouri
  4. Boys Town, Nebraska
  5. Canton, Ohio
  6. Koblenz,
  7. Rosenheim,
  8. Wesel,
  9. Balvi,
  10. Daugavpils,
  11. Rezekne,
  12. Riga,
  13. Riga,
  14. Vilnius,
  15. Vilnius,
  16. Vilnius,
  17. Kamnik,
  18. Ljubljana,
  19. Maribor,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
AsthmaRandomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284
  1. Hallein,
  2. Linz,
  3. Neumarkt am Wallersee,
  4. Schlüsslberg,
  5. Thalheim bei Wels,
  6. Berlin,
  7. Berlin,
  8. Frankfurt,
  9. Hamburg,
  10. Hannover,
  11. Mainz,
  12. Schwerin,
  13. Wiesbaden,
  14. Wiesloch,
  15. Ivano-Frankivsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kiev,
  19. Kiev,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
Official Title  ICMJE The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma
Brief Summary The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: IMA-026
  • Other: Placebo
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: IMA-026
  • Placebo Comparator: B
    Intervention: Other: Placebo
Publications * Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1007-14. doi: 10.1164/rccm.201008-1210OC. Epub 2010 Nov 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: July 29, 2008)
24
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2009
Actual Primary Completion Date June 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy men and women 18 to 60 yrs with mild allergic asthma
  2. only asthma med is short-acting bronchodilator used not more than twice weekly
  3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Exclusion Criteria:

  1. Upper respiratory infection or asthma exacerbation with 4 weeks of screening
  2. Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of test article administration
  3. Positive radiographic findings indicative of respiratory disease other than asthma
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00725582
Other Study ID Numbers  ICMJE 3192K1-1002
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP